Stay updated with breaking news from Jay Feingold. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Financing round led by Ysios Capital and Gilde Healthcare with participation from Novartis Venture Fund, New Enterprise Associates, and Lightstone Ventures...
• Prioritized pipeline to focus on most advanced programs while maintaining financial flexibility to pursue business development opportunities • Appointed Rachel Humphrey, M.D., a... | August 15, 2022
/PRNewswire/ -- Biosion, Inc., a global R&D stage biotechnology company, today announced that Biosion and Pyxis Oncology (NASDAQ: PYXS) have entered into an...
As a barometer of the rude health biotechs continue to find themselves in on Wall Street, Big Pharma-backed oncology player Pyxis Oncology is upping its IPO.
ZYNLONTA™ LOTIS-2 updated data includes median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory DLBCLSubgroup analyses include patients with double- / triple-hit, advanced stage or transformed DLBCL, DLBCL refractory to first-line therapy, and patients older than 65LAUS...